- 612studies on this subject, of 27,380 in the library
- 587peer-reviewed
- 1968–2026years published
- 48median usefulness score out of 100
These counts and lists are worked out from the library itself each time the page loads. A score rates how much weight a study can bear — its design, journal, evidence and recency — not whether its result is good news. How we score a study.
The 20 highest-scoring studies
-
A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease
By pooling genetic data from 1,126,563 people, this study found seven genetic regions linked to late-onset Alzheimer's disease that had not been identified before, and it points to microglia, immune cells and protein breakdown ("protein catabolism") as relevant. The authors say only "a fraction" of the genetic variants behind Alzheimer's are known and expect larger analyses to find more. These are risk associations to guide research, not a test, treatment or way to prevent the disease.
- Alpha-synuclein co-pathology in a real-world early Alzheimer's disease cohort
-
Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden
Two surveys of people aged 75 and over in central Stockholm, in 1987-1989 (1,700 people) and 2001-2004 (1,575 people), diagnosed dementia with the identical procedure, so the two periods can be compared fairly. The authors report that the changes "suggest decreasing incidence" of dementia, meaning fewer new cases. The summary stored here gives no figures and names no cause. This is one district's trend in how often dementia occurs. It does not show that anything prevents dementia.
-
Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis
This review and meta-analysis synthesized cohort study data on the association between total serum cholesterol and late-life cognitive outcomes including Alzheimer's disease, vascular dementia, any dementia, mild cognitive impairment, and cognitive decline. It examines a risk association only and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuum
By analyzing cerebrospinal fluid proteins across the Alzheimer's disease continuum, this study identified over 2,000 proteins that are dysregulated and grouped them into stages involving processes like neuronal death, microglial changes, and brain plasticity. Machine learning models built from these proteins predicted Alzheimer's biomarker status and clinical status with high accuracy and could identify people who would later convert to Alzheimer's disease.
- Limbic-Predominant Age-Related TDP-43 Encephalopathy: Medical and Pathologic Factors Associated With Comorbid Hippocampal Sclerosis
- Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies
-
Body mass index in midlife and dementia: Systematic review and meta-regression analysis of 589,649 men and women followed in longitudinal studies
This meta-analysis of 19 studies on 589,649 participants found that midlife obesity was associated with a higher risk of dementia. It examines a risk association and provides no treatment, cure or prevention.
-
Systematic evaluation of the associations between environmental risk factors and dementia: An umbrella review of systematic reviews and meta-analyses
This umbrella review of meta-analyses examined associations between nongenetic environmental factors and dementia, assessing 76 unique associations. It looks at possible risk factors and provides no treatment, cure or prevention.
- Misfolded α-synuclein co-occurrence with Alzheimer's disease proteinopathy
-
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014
This review of 30 years of Alzheimer's drug development found that only four cholinesterase inhibitors and memantine have shown sufficient safety and efficacy for marketing approval. The other drugs tested were probably ineffective, though inadequate clinical development methods have also been blamed for the failures.
-
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect
This longitudinal study followed cognitively normal subjects to determine when memory decline diverges among those with different APOE epsilon4 statuses. It found that the age at which memory decline diverges among homozygous carriers, heterozygous carriers, and noncarriers was previously unknown.
-
Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons
This longitudinal study tested whether cerebral amyloid angiopathy is related to Alzheimer's disease dementia and decline in multiple cognitive systems in old age, independent of AD plaque and tangle pathology. It followed 1,113 participants from two longitudinal clinical-pathologic studies of aging with annual cognitive testing for a mean of 7.1 years before death.
-
Sex differences in Alzheimer's disease and common neuropathologies of aging
This study used post-mortem data from 1,453 participants in two community-based studies to examine sex differences in Alzheimer's disease and other brain pathologies. It is a pathological description and does not report a treatment, cure, or prevention.
- Limbic-predominant age-related TDP-43 encephalopathy in Black and White decedents
-
Single-cell multiregion dissection of Alzheimer's disease
This study built a single-cell atlas of six brain regions from 283 post-mortem samples, identifying 76 cell types and vulnerable populations of excitatory neurons. It is a descriptive map of brain tissue and does not test a treatment, cure, or prevention for Alzheimer's disease.
-
Cerebral amyloid angiopathy pathology and cognitive domains in older persons
This cohort study of 404 older persons examined how the severity of cerebral amyloid angiopathy relates to cognitive domains. It describes an association between a vascular pathology and cognition and does not test a treatment, cure, or prevention.
-
Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease
This case-control study tested whether lifetime-acquired loss of chromosome Y in blood cells is associated with Alzheimer's disease. It reports an association only and does not show any treatment, cure or prevention.
- Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy
- Associations between misfolded alpha-synuclein aggregates and Alzheimer's disease pathology in vivo
See all 612 studies in Brain tissue and pathology, with filters →
Newest additions on this subject
- Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival
- TMEM106B C-Terminal fragment aggregation exacerbates α-synuclein and TDP-43 proteinopathy phenotypes
- Repeated VU0155069 Treatment Is Associated with Region- and Pathological Stage-Specific Dendritic Spine Remodeling in Female 3xTg-AD Mice
- A coordinated and reproducible multicellular response to AD pathology
- A brain immune phenotype independent of Alzheimer’s Disease associates with amyloid susceptibility and systemic inflammation
- Coordinated cellular responses track cognitive outcomes in Alzheimer’s disease
- Selective vulnerability: validation of atypical neurodegenerative disease variants in histopathological reference cohorts
- Systematic identification of perioperative neurocognitive disorder related biomarkers in Alzheimer’s disease and development of machine learning-based diagnostic models
- Intrastriatal injection of amplified Lewy body dementia (LBD) fibrils in mice results in accumulation of fibrils with LBD structure and neurodegeneration
- ALS-associated mutations reveal a conserved C-terminal self-assembly module in the TDP-43 low-complexity domain
All 612 studies in Brain tissue and pathology, newest first →
What the library holds on this subject
By review status
| Status | Studies |
|---|---|
| Peer-reviewed | 587 |
| Preprint — not yet peer-reviewed | 23 |
| Retracted — do not rely on it | 2 |
By strength of evidence
| Rated in our summary | Studies |
|---|---|
| low | 483 |
| moderate | 106 |
| not rated | 13 |
| high | 10 |
Most frequent journals
| Journal | Studies |
|---|---|
| Neurology | 31 |
| Acta neuropathologica | 30 |
| Brain : a journal of neurology | 26 |
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 18 |
| Annals of neurology | 18 |
| Alzheimer s & Dementia | 12 |
| Proceedings of the National Academy of Sciences of the United States of America | 12 |
| Archives of neurology | 11 |
| Nature | 11 |
| Journal of neuropathology and experimental neurology | 10 |
Studies by year published
| Year | Studies | Bar |
|---|---|---|
| 2026 | 58 | |
| 2025 | 114 | |
| 2024 | 17 | |
| 2023 | 13 | |
| 2022 | 16 | |
| 2021 | 16 | |
| 2020 | 21 | |
| 2019 | 7 | |
| 2018 | 11 | |
| 2017 | 14 | |
| 2016 | 14 | |
| 2015 | 18 | |
| 2014 | 10 | |
| 2013 | 19 | |
| 2012 | 24 | |
| 2011 | 21 | |
| 2010 | 23 | |
| 2009 | 20 | |
| 2008 | 13 | |
| 2007 | 15 | |
| 2006 | 14 | |
| 2005 | 8 | |
| 2004 | 16 | |
| 2003 | 12 | |
| 2002 | 12 | |
| 2001 | 7 | |
| 2000 | 10 | |
| 1999 | 9 | |
| 1998 | 6 | |
| 1997 | 6 | |
| 1996 | 4 | |
| 1995 | 4 | |
| 1994 | 12 | |
| 1993 | 4 | |
| 1992 | 3 | |
| 1991 | 6 | |
| 1990 | 2 | |
| 1989 | 1 | |
| 1988 | 3 | |
| 1986 | 1 | |
| 1984 | 2 | |
| 1983 | 2 | |
| 1982 | 1 | |
| 1980 | 1 | |
| 1970 | 1 | |
| 1968 | 1 |
Counts the 612 studies with a usable publication date. The library is a large sample of published work, not a complete index, so these counts describe the library, not the whole field.
Other subjects in the library
- Getting a diagnosis
- Biomarkers
- Clinical trials
- Prevention and risk
- Caregiving
- How common it is
- Costs and economics
- Genetics
- Laboratory science
- Disease mechanisms
- Vascular contributions
- Prevention trials
- Clinical safety
- Health systems and care delivery
- End-of-life care
- Risk factors
- Digital health tools
- Treatments
- Disparities
- Mild cognitive impairment
- Risk genes beyond APOE
- Brain scans and imaging
- TREM2 and immune genetics
- Cognitive tests and assessment
- Lewy body dementia
- Down syndrome and Alzheimer's
- Long-term cohort studies
- Inflammation and the immune system
- Tau biomarkers
- Drug development
- Hippocampus size on brain scans